Watson Pharmaceuticals Inc. has become the fourth generics maker hit with a patent suit by Cephalon Inc. for planning to offer a generic version of narcolepsy drug Nuvigil®. Cephalon filed suit against Watson on January 5, alleging that Watson’s abbreviated new drug application for generic Nuvigil® infringes a Cephalon patent. Cephalon had previously filed similar suits over planned generic Nuvigil® against Mylan Pharmaceuticals Inc., Actavis Group and Teva Pharmaceuticals USA Inc. Nuvigil® is a prescription drug used to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, sleep apnea, and shift work sleep disorder. Cephalon is represented in this matter by Finnegan.
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Press Release
District Court Rules in Favor of Finnegan Client Cephalon to Uphold Patent for Nuvigil®
March 30, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.